Tiziana Life Sciences ( (TLSA) ) has shared an update.
On February 25, 2025, Tiziana Life Sciences announced the nearing completion of a preclinical study for their nasal anti-CD3 treatment, foralumab, which could provide a novel solution for long COVID. This treatment targets microglial activation, a key factor in brain inflammation associated with long COVID, potentially alleviating neurological and psychiatric symptoms. Previous studies have shown foralumab’s effectiveness in reducing inflammation in COVID-19 patients and its potential in treating neuroinflammatory diseases like multiple sclerosis. The announcement highlights Tiziana’s continued efforts to address complex medical challenges with innovative therapies.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. Their lead candidate, intranasal foralumab, is a fully human anti-CD3 monoclonal antibody, which has shown promising safety and efficacy in clinical studies. The company aims to improve immunotherapy delivery methods, offering potential advantages over traditional intravenous approaches.
YTD Price Performance: 33.09%
Average Trading Volume: 656,770
Technical Sentiment Consensus Rating: Sell
Current Market Cap: $100.2M
For a thorough assessment of TLSA stock, go to TipRanks’ Stock Analysis page.